SGLT2 Inhibitors and the GlycoMark Test


Dear Healthcare Professionals,

As an update to our July report on SGLT2 inhibitors and the GlycoMark 1,5-AG test, we are pleased to summarize new data presented at the ADA Advancing Precision Diabetes Medicine meeting in October. In the study “GlycoMark 1,5-Anhydroglucitol as a Biomarker of SGLT2 Inhibitor Effect”, Dahlen, et al. describe the observed relationship between the GlycoMark 1,5-AG test and the effect of SGLT2 inhibitors.


As shown in Fig 1, patients with diabetes NOT on SGLT2 inhibitor treatment had GlycoMark 1,5-AG test results in the upper ABNORMAL range, indicating recent hyperglycemia and hyperglycemic excursions. Patients with diabetes ON-TREATMENT of an SGLT2 inhibitor had extremely low GlycoMark test results, ≤2 μg/mL, suggesting treatment compliance and desired SGLT2 inhibitor effect.


GlycoMark 1,5-AG Test Results Compared to SGLT2 Inhibitor Treatment Status1

Figure 1
Figure 1

The optimal cutoff for identifying the SGLT2 inhibitor effect was a GlycoMark result < 2.0 ug/mL, which was validated in an independent dataset and found to have a sensitivity of 92.2% and specificity of 100% for the detection of an SGLT2 inhibitor effect in diabetes patients with A1C < 8% (Table 1).

Diagnostic Performance Validation1

Table 1
Table 1


SGLT2 inhibitors lower glucose levels in patients with diabetes by preventing the kidneys from reabsorbing glucose, triggering glycosuria.2

The GlycoMark test, a measure of 1,5-anhydroglucitol (1,5-AG), is highly sensitive to glycosuria and is used to detect recent hyperglycemia and hyperglycemic excursions. (Abnormal <10 μg/mL).  The GlycoMark test is not specifically indicated to detect or measure the presence of SLGT-2 inhibitors.

For study questions or to receive information about the presented data from Clinical Affairs, please email

Dr. Jeff Dahlen is VP of Clinical and Scientific Affairs at GlycoMark.

1Dahlen JR, et al. GlycoMark 1,5-Anhydroglucitol as a Biomarker of SGLT2 Inhibitor Effect. Poster presented at the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium, October 2019, Madrid, Spain.
2Garber AJ, et al. 2018 AACE/ACE T2D Management, Endocr Pract. 2018;24(No. 1).